|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results suggest that downregulation of tumor βIII- and βV-tubulins is correlated with taxane resistance in BC.
|
30126203 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In our efforts to improve the efficacy of taxane-based microtubule (MT) stabilizing agents against tumor drug resistance mediated by multiple mechanisms, two clinically relevant factors were focused: i.e., P-glycoprotein and βIII-tubulin overexpression.
|
28624703 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High levels of βIII-tubulin isotype expression are associated with tumor aggressivity and drug resistance.
|
28567478 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
βIII-tubulin overexpression is linked to aggressive tumor features and genetic instability in urinary bladder cancer.
|
28025079 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
βIII-Tubulin decreases the reliance of cells on glycolytic metabolism, priming them to cope with variable nutrient supply present within the tumor microenvironment.
|
27207668 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Special focus is placed on (1) the aberrant overexpression of βIII-tubulin, a survival factor associated with hypoxic tumor microenvironment and dynamic instability of microtubules; (2) the ectopic overexpression of γ-tubulin, which in addition to its conventional role as a microtubule-nucleating protein has recently emerged as a transcription factor interacting with oncogenes and kinases; (3) the microtubule-severing ATPase spastin and its emerging role in cell motility of glioblastoma cells; and (4) the modulating role of posttranslational modifications of tubulin in the context of interaction of microtubules with motor proteins.
|
25976261 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, we assessed the role of βIII-tubulin in regulating tumor growth and metastases using an orthotopic pancreatic cancer mouse model.
|
25544769 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The βIII isotype of tubulin is associated with drug resistance and tumor aggressivity.
|
26416565 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
βIII-Tubulin expression was associated with PTEN (P < 0.0001) when all tumors were analyzed, but also in the subgroups of ERG-negative and ERG-positive cancers.
|
24378408 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
|
23941826 |
2013 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
This study aimed at examining whether βIII-tubulin (TUBB3), present in various types of normal tissues and cancer, is a biomarker for the response of colorectal neoplasms to paclitaxel.
|
30711942 |
2019 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
This study aimed at examining whether βIII-tubulin (TUBB3), present in various types of normal tissues and cancer, is a biomarker for the response of colorectal neoplasms to paclitaxel.
|
30711942 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Tissue microarray analysis showed that overexpression of βIII-tubulin correlated to NSCLC malignant grading.
|
30429459 |
2018 |
|
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Among them, the βIII isotype is overexpressed in many aggressive and metastatic cancers and may serve as a prognostic marker in certain types of cancer.
|
27943021 |
2017 |
|
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
We discuss several groups of compounds that have been designed to differentially bind with specific affinities for tubulin β isotypes, especially in regard to βIII, which is commonly over-expressed in cancer.
|
28056740 |
2017 |
|
Primary malignant neoplasm
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Among them, the βIII isotype is overexpressed in many aggressive and metastatic cancers and may serve as a prognostic marker in certain types of cancer.
|
27943021 |
2017 |
|
Primary malignant neoplasm
|
0.050 |
AlteredExpression
|
group |
BEFREE |
We discuss several groups of compounds that have been designed to differentially bind with specific affinities for tubulin β isotypes, especially in regard to βIII, which is commonly over-expressed in cancer.
|
28056740 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Non-small cell lung cancer (NSCLC) survival rates are dismal and high βIII-tubulin expression is associated with chemotherapy drug resistance and tumor aggressiveness in this disease.
|
27207668 |
2016 |
|
Non-Small Cell Lung Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
The purpose of the present study was to evaluate the associations between stathmin and β-III-tubulin expression and treatment response and survivals in patients with non-small cell lung cancer (NSCLC).
|
25894372 |
2015 |
|
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
βIII-t overexpression was linked to increasing malignancy in glial tumors and described to determine the onset of resistance to chemotherapy.
|
25244496 |
2014 |
|
Primary malignant neoplasm
|
0.050 |
AlteredExpression
|
group |
BEFREE |
βIII-t overexpression was linked to increasing malignancy in glial tumors and described to determine the onset of resistance to chemotherapy.
|
25244496 |
2014 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Increased abundance of βII- and βIII-tubulin isotypes in cancer cells confers resistance to vinca and taxoid site drugs; however, the role of these isotypes in the acquired resistance of cancer cells to non-vinca or non-taxoid site binding agents has not been described.
|
22180309 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Prospective evaluation of βIII/βV-tubulin expression in NSCLC is warranted.
|
22836512 |
2012 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
Increased abundance of βII- and βIII-tubulin isotypes in cancer cells confers resistance to vinca and taxoid site drugs; however, the role of these isotypes in the acquired resistance of cancer cells to non-vinca or non-taxoid site binding agents has not been described.
|
22180309 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
In this study, the functional significance of specific β-tubulin isotypes in intrinsic sensitivity to epothilone B was investigated using siRNA gene knockdown against βII-, βIII- or βIVb-tubulins in two independent non-small cell lung cancer (NSCLC) cell lines, NCI-H460 and Calu-6.
|
21738778 |
2011 |